Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Sales: 2022-2025

Historic Return on Sales for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 0.06%.

  • Kiniksa Pharmaceuticals International's Return on Sales rose 28.00% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 28.00%. This contributed to the annual value of -0.10% for FY2024, which is 12.00% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Return on Sales of 0.06% as of Q3 2025, which was up 563.78% from 0.01% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Return on Sales peaked at 26.74% during Q4 2022, and registered a low of -1.33% during Q2 2022.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Return on Sales value was -0.04% (recorded in 2025), while the average stood at 1.47%.
  • Within the past 5 years, the most significant YoY rise in Kiniksa Pharmaceuticals International's Return on Sales was 579bps (2023), while the steepest drop was 2,697bps (2023).
  • Kiniksa Pharmaceuticals International's Return on Sales (Quarterly) stood at 26.74% in 2022, then tumbled by 2,697bps to -0.22% in 2023, then climbed by 12bps to -0.10% in 2024, then rose by 28bps to 0.06% in 2025.
  • Its last three reported values are 0.06% in Q3 2025, 0.01% for Q2 2025, and -0.04% during Q1 2025.